Pay attention to breast cancer prevention and improve the survival rate of advanced patients
"2020 Forum on New Strategies for Advanced Breast Cancer Chemotherapy" Held in Beijing
People's Daily Online, Beijing, August 27. Hair loss, pain, nausea and vomiting, unable to take care of themselves... This is the state of a breast cancer patient who came to the hospital for chemotherapy received in 2017 by Mei Zhihong, head nurse of the Cancer Hospital of the Chinese Academy of Medical Sciences. "I can cook for my family!" With the psychological intervention of the doctors and nurses, she was much happier when she came to chemotherapy for the second time. By the fifth cycle of chemotherapy, this lady had become a volunteer in the hospital, assisting in psychological interventions for new breast cancer patients.
In order to care for women’s health, further extend the overall survival of patients with advanced breast cancer, and help advance cancer prevention and treatment, on August 23, co-hosted by People's Daily Online, People’s Health, China Health Promotion Foundation and National Cancer Center, Eisai (China) The "2020 New Strategies Forum for Advanced Breast Cancer Chemotherapy" supported by the pharmaceutical industry was held in the New Media Building of the People's Daily.
Li Zhixin, deputy director of the Maternal and Child Health Center of the China Centers for Disease Control and Prevention, said that caring for women's health must unswervingly implement the policy of prevention first, adhere to the combination of prevention and treatment, joint prevention and control, and group prevention and group control. He pointed out that in the new era, the health of women and children is facing new challenges, and the continued growth of cervical cancer and breast cancer in my country has not been reversed. The Chinese government attaches great importance to the prevention and control of women’s two cancers. With the active efforts of various localities, the two cancer inspection projects carried out in many places have expanded from rural to urban and rural areas. The coverage of the two-cancer free examination has continued to expand, and the two-cancer examination has achieved remarkable results.
"From the current situation of women's health in China, women's health problems caused by regional differences and unbalanced development are more obvious. Based on the number of cases and deaths, breast cancer has become a cancer with a rapid increase in the mortality rate of urban women." Chang Yingming, Lifetime Honorary Vice President and Secretary-General of the China Health Promotion Foundation, pointed out in his speech that in order to further improve the level of diagnosis and treatment of breast cancer, the country has made breast cancer the first tumor for single-disease quality control trials. Medical institutions at all levels across the country have gradually established a quality control system for standardized diagnosis and treatment of breast cancer to ensure the diagnosis and treatment of more patients and the maximum health benefits.
Zhang Jianzhong, Vice President and Head of the Pharmaceutical Business Division of Eisai (China) Pharmaceutical Co., Ltd., hopes to continue to introduce more global innovative drugs for Chinese patients. Next, Eisai will also assist in the “Hundred City Tour of New Strategies for Advanced Breast Cancer Chemotherapy” in more than 30 cities across the country to help grassroots doctors improve their business and service capabilities, strengthen the maternal and child health public health service system, and further promote breast cancer Prevention and control work.
"I have always advocated not giving up on advanced breast cancer, because now the median survival period of some special types of advanced patients can be close to five years, that is, to reach the level of clinical cure." National New Drug (Antibiotics), Chinese Academy of Medical Sciences Cancer Hospital In a speech, Xu Binghe, director of the Cancer Research Center, pointed out that in addition to treatment, full-process and full-cycle management can also enable patients to achieve the ultimate goal of treatment. It is hoped that all parties will pay attention to the patients with advanced stages and bring them more hope.
In the keynote speech session, Hu Xichun, director of the Department of Oncology, Fudan University Cancer Hospital, introduced "my country's new chemotherapy strategy for advanced breast cancer" via live connection. He believes that although the treatment of advanced breast cancer includes endocrine therapy, molecular targeted therapy, and even immunotherapy, almost every patient will use chemotherapy. This requires that every doctor who treats breast cancer should use chemotherapy drugs well.
In response to "the new standard of chemotherapy for advanced triple-negative breast cancer in the post-yew era," Wang Biyun, chief physician of the Department of Oncology, Fudan University Cancer Hospital, said in a connection that China's breast cancer targeted therapy has developed rapidly and has gradually entered the era of precision treatment . The treatment goal of advanced breast cancer is to prolong survival and improve the quality of life. Chemotherapy is still the cornerstone of the treatment of various types of breast cancer. The treatment principle of advanced triple-negative breast cancer is the benefit of the patient's overall survival.
In the first round of case discussions, Cao Jun, deputy chief physician of the Department of Internal Medicine, Fudan University Cancer Hospital, shared two cases of triple-negative breast cancer; Nie Jianyun, director of the Third Department of Breast Surgery of Yunnan Cancer Hospital, participated in the discussion and said that from the case It can be seen that the decision-making position of chemotherapy has not declined, but has been strengthened, and even the strategy of chemotherapy should be appropriately adjusted; Yang Feiyue, deputy director of the Department of Oncology, Guizhou Provincial People’s Hospital, said that in triple-negative breast cancer, it is especially widespread. For triple-negative breast cancer, the timeliness status of chemotherapy must not be shaken; Yuan Zhongyu, chief physician of Sun Yat-sen University’s Cancer Hospital, hopes to use this platform to make appeals to provide patients with more convenience in terms of price and medical insurance in the future.
In the second round of case discussions, Li Qiao, deputy chief physician of the Department of Internal Medicine, Cancer Hospital of the Chinese Academy of Medical Sciences, shared the case and pointed out that although the current proportion of triple-negative breast cancer is not high, the proportion of advanced patients is higher than that of early patients. At the same time, patients with triple-negative breast cancer often have worse prognosis than other types; Song Guohong, chief physician of the Department of Breast Oncology, Peking University Cancer Hospital, participated in the discussion and said that for advanced breast cancer, one emphasizes the efficacy and the other emphasizes the quality of life. According to evidence-based medicine, the remission rate of combined chemotherapy may be higher, while the quality of life of single-agent chemotherapy is relatively better, and the side effects are relatively low. Therefore, it is necessary to formulate individualized treatment strategies based on individual differences in patients; Zheng Yabing, deputy director of the Department of Breast Oncology, Zhejiang Cancer Hospital, believes through the connection that it is difficult to cure advanced breast cancer patients, so it is still necessary for patients to have a very Good quality of life, prolong survival. After achieving a certain effect, there are three main modes of maintenance treatment: original drug maintenance, single drug maintenance and dressing maintenance; Ma Fei, chief physician of the Department of Oncology, Cancer Hospital of the Chinese Academy of Medical Sciences, concluded that in addition to chemotherapy, for triple-negative breast cancer Strategies such as targeted therapy and immunotherapy can also be adopted, and selections should be made according to individual conditions during clinical practice.
At the meeting, Xu Binghe introduced the "China Blue Book of Advanced Breast Cancer Chemotherapy" and explained the importance of standardized diagnosis and treatment of breast cancer.
In the roundtable discussion session of the head nurse, Mei Zhihong, head nurse of the Cancer Hospital of the Chinese Academy of Medical Sciences, shared that for patients with advanced breast cancer, symptom care is critical. The symptoms of advanced breast cancer include the symptoms caused by the disease itself and the symptoms produced during the treatment process, such as pain, nausea, vomiting, hair loss, etc., which bring greater psychological pressure to the patient, and the patient should be treated from the perspective of symptom management; Zhongshan Shi Simei, head nurse of the University Cancer Hospital, believes that safe and accurate medication is the most important safety guarantee for patients for nursing staff. At the same time, in terms of nursing operation and medication safety, it is not only necessary to grasp the accurate dosage and accurate time, but also to ensure safety in the medication input pipeline or method. "
"Love, All the Way", a short story about a patient with advanced breast cancer played at the forum, led the guests to truly integrate into the patient's mental journey, and had a more profound feeling about the treatment of advanced breast cancer patients. Xu Binghe called in his concluding speech to continue to give more care, love and reasonable treatment to patients with advanced breast cancer.
During the forum, "Healthy China Tour-2020 National Breast Cancer Prevention and Control Series Activities" was officially launched. Leaders and experts from the three venues in Beijing, Shanghai and Guangzhou participated in the launching ceremony.